CureMatch
×
  • Physicians
  • Patients
  • Employers
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact
  • Login

Artificial Intelligence Facilitates Drug Combination Therapy Recommendations Bioinformatics Journal

Artificial Intelligence Facilitates Drug Combination Therapy Recommendations Bioinformatics Journal
PublicationsValidation

CureMatch’s Tsigelny is a featured author in Briefings in Bioinformatics journal with a review on artificial intelligence’s usefulness in drug combination therapy recommendations.

SAN DIEGO, CA – February 12, 2018: Igor F. Tsigelny, Ph.D., Co-founder and Chief Science Officer at CureMatch®, is the author of “Artificial intelligence in drug combination therapy” in Briefings in Bioinformatics Journal1. This 15-page intensive research review with 137 references explores several artificial intelligence (AI) methods that have been successfully implemented in combination drug therapy including HIV, hypertension, infectious diseases, and cancer. The data clearly shows that rule-based expert systems in tandem with machine learning algorithms poses a promising direction in the field of biomedical informatics and the advancement of combination therapy.

The concept of drug combination therapy has long been a scientific area of interest. Of note, the classical work devoted to the synergism of drugs by Loewe published in 1928 is still being used in calculations for optimal drug combinations. The development of combination drug therapies has been necessitated by the nature of complex diseases. One drug usually cannot target all the necessary points of intervention. For example, oncologists often meet cancer patients with more than five molecular aberrations in their genomic profiles.

In recent years, there has been an explosion of available information related to the biomedical parameters of patients as well as the properties of drugs. Regarding patients, large “-omic” (genomic/proteomic/metabolomic) data sets are now available in addition to the histology, history of treatments, pretreatment state of the organism, etc. Regarding drugs, hundreds of 2D, 3D, and even 4D molecular descriptors for medicines are now available. Further accounting for potential changes to the genetic profile during disease progression, the ability to optimize drug combinations for each patient is rapidly moving beyond the comprehension and capabilities of an individual physician.

Targeted combination therapy is increasingly the choice treatment for many complex human diseases, particularly those resulting from genetic aberrations (such as cancer). However, selecting the most promising combinations for each patient can be a daunting task, especially since combining two or more drugs can often lead to effects beyond the simple addition of their single impacts. Consider a cancer treatment regimen to address six or more specific genetic alterations. Factoring multiple possible dosing regimens, the number of potential combinations rapidly multiplies, achieving numbers as high as 1011. As the number and type of genetic alterations can vary widely from patient to patient, these types of choices must be considered for each individual—extending beyond the capabilities of primary care physicians.

Computational approaches are clearly required in the optimization of combination therapies, and many artificial intelligence (AI) methods are being utilized. Tsigelny describes the main concepts of machine-learning systems as well as deep-learning artificial neural networks towards practical biomedical science applications. The research succinctly addresses the advantages and disadvantages of using different types of artificial intelligence to address specific problems, and in particular combination drug therapy. Machine learning systems in combination therapy should consider compound-related, biochemical result-related, cell-related, and patient-related parameters. Valuable information for beginners and professionals in the field including websites to download or use machine learning programs are presented.

“The future of complex disease treatment is being driven by machine learning across rapidly growing datasets of drug and genomic/proteomic information,” stated Tsigelny. “The one practical way clinicians can distill the overwhelming combination drug therapy options into actionable intelligence for patient care is through artificial intelligence (AI).”

Igor F. Tsigelny is an expert in intelligent computing systems as applied to cancer who guides the development of the CureMatch precision oncology technology. CureMatch’s primary objective is to determine optimal combinations of anticancer drugs. Developing AI machine-learning systems allows CureMatch to score and rank Personalized Combination Therapy® options to improve the precision of cancer treatment recommendations.

###

Journal Reference
[1] Artificial intelligence in drug combinations therapy
Igor F. Tsigelny 1-4*
1 San Diego Supercomputer Center, 2 Moores Cancer Center, 3 Department of Neurosciences University of California at San Diego, 4 CureMatch, Inc.
Briefings in Bioinformatics Vol. 19, Issue 2, February 2018
https://doi.org/10.1093/bib/bby004

About Briefings in Bioinformatics
Briefings in Bioinformatics is an international forum for researchers and educators in the life sciences. The journal will also be of interest to mathematicians, statisticians and computer scientists who apply their work to biological problems. The journal publishes reviews for the users of databases and analytical tools of contemporary genetics, molecular and systems biology and is unique in providing practical help and guidance to the non-specialist in computerized methodology. Papers range in scope and depth, from the introductory level to specific details of protocols and analyses encompassing bacterial, plant, fungal, animal and human data.

About CureMatch®
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations in cost-effective PreciGENE reports. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com

Media Contact
Name: Larissa Anderson
Company: CureMatch
Phone: 858-859-2873
Email: press@curematch.com

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

  • CureMatch Announces the Addition of John S. Link, Jordan Shlain and Greg Simon to Advisory Board

    Dr. Link, Dr. Shlain and Mr. Simon all bring deep entrepreneurial experience in the medical...

  • CureMatch and Alliance Care Technologies Announce Partnership to Bring Precision Cancer Treatment to More Patients

    CureMatch, Inc., and Alliance Care Technologies International (ACT) have announced a strategic partnership to bring...

  • MedNews: Precision Medicine Clubhouse Presentation with Dr. Kurzrock

    Precision medicine tailors treatments, practices, and products to the specific needs of a patient and...

  • Interview with Dr. Razelle Kurzrock of CureMatch: Why Patients Need Precision Cancer Medicine

    In this dynamic interview, Chief Medical Advisor, Dr. Kurzrock, sits down with Michelle Morand, Co-Founder...

  • New Study Validates Payer/Physician Use of AI to Cut Wasteful Spending on High-Cost, Low-Value Cancer Drugs

    The Research Consortium announced the release of a new study today that challenges common misconceptions...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 284-0488

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service Jan 4

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal Jul 26

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

  • CureMatch Announces the Addition of John S. Link, Jordan Shlain and Greg Simon to Advisory Board Jul 21

    Dr. Link, Dr. Shlain and Mr. Simon all bring deep entrepreneurial experience in the medical...

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data